论文信息 - Is all cancer therapy immunotherapy?

Is all cancer therapy immunotherapy?

Researchers must renew efforts to decipher how standard chemotherapies enhance the effects of targeted immunotherapeutic agents (Müller et al., this issue). Researchers must renew efforts to decipher how standard chemotherapies enhance the effects of targeted immunotherapeutic agents (Müller et al., this issue).

M. Belvin | I. Mellman

[1] N. Harbeck,et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade , 2015, Science Translational Medicine.

[2] T. Gajewski. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. , 2015, Seminars in oncology.

[3] K. Anderson,et al. Immunotherapy for the Treatment of Breast Cancer , 2015, Current Oncology Reports.

[4] D. Lardinois,et al. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity , 2014, Cancer Immunology, Immunotherapy.

[5] Ira Mellman,et al. Antibody Therapeutics in Cancer , 2013, Science.

[6] D. Petrylak,et al. Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.